Get the Stockscreener App
86.57
6.09%
4.97
After Hours:
87.01
0.44
+0.51%
Mirum Pharmaceuticals Inc stock is traded at $86.57, with a volume of 881.09K.
It is up +6.09% in the last 24 hours and up +32.37% over the past month.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
See More
Previous Close:
$81.60
Open:
$82.01
24h Volume:
881.09K
Relative Volume:
1.28
Market Cap:
$4.47B
Revenue:
$379.25M
Net Income/Loss:
$-77.34M
P/E Ratio:
-53.70
EPS:
-1.6122
Net Cash Flow:
$-27.87M
1W Performance:
+10.89%
1M Performance:
+32.37%
6M Performance:
+61.93%
1Y Performance:
+106.12%
1-Day Range:
$81.62
$86.79
1-Week Range:
$73.82
$86.79
52-Week Range:
$36.88
$86.79
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
86.57 | 4.22B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-25 | Initiated | TD Cowen | Buy |
| Aug-11-25 | Resumed | Stifel | Buy |
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price Is Right But Growth Is Lacking After Shares Rocket 34% - 富途牛牛
Mirum Pharmaceuticals begins Phase 2 trial for Fragile X syndrome drug - Investing.com Nigeria
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals - Business Wire
MarketsMedicine Hat News - FinancialContent
Can Mirum Pharmaceuticals Inc. (08D) stock test all time highsTrade Performance Summary & Weekly Hot Stock Watchlists - ulpravda.ru
Is Mirum Pharmaceuticals Inc. (08D) stock undervalued after correctionJuly 2025 Institutional & Risk Managed Investment Entry Signals - ulpravda.ru
Will Mirum Pharmaceuticals Inc. stock benefit from infrastructure spendingWeekly Stock Report & Risk Controlled Daily Plans - ulpravda.ru
How supply chain issues affect Mirum Pharmaceuticals Inc. stockJuly 2025 Action & Fast Gaining Stock Reports - ulpravda.ru
Can Mirum Pharmaceuticals Inc. stock reach $100 price targetQuarterly Profit Review & Risk Adjusted Buy/Sell Alerts - ulpravda.ru
Mirum Pharmaceuticals to raise $68.5M in private placement with TCGX - MSN
Mirum Pharmaceuticals stock hits all-time high at 82.65 USD By Investing.com - Investing.com Nigeria
How Investors May Respond To Mirum Pharmaceuticals (MIRM) Expanding Livmarli And Gaining J.P. Morgan Spotlight - Yahoo Finance
Is Mirum Pharmaceuticals Inc. stock supported by strong fundamentalsInstitutional Holding Changes & High Return Investment Plans - ulpravda.ru
Mirum Pharmaceuticals, Inc.common stock (NQ: MIRM - FinancialContent
How Mirum Pharmaceuticals Inc. stock compares to growth peersMorning Star Patterns & Free Skyrocketing Profit Margins - ulpravda.ru
Should you invest in Mirum Pharmaceuticals (MIRM)? - MSN
Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
Mirum Pharmaceuticals stock hits all-time high at 82.65 USD - Investing.com India
What hedge fund activity signals for Mirum Pharmaceuticals Inc. stockEarnings Date Calendar & Low Cost Trading Plans - ulpravda.ru
Mirum Pharmaceuticals (MIRM) price target increased by 16.25% to 104.35 - MSN
Should You Invest in Mirum Pharmaceuticals (MIRM)? - Insider Monkey
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A 36.45% Potential Upside Captivates Investors - DirectorsTalk Interviews
Gains Recap: Will Mirum Pharmaceuticals Inc stock benefit from infrastructure spendingWeekly Investment Summary & Short-Term High Return Strategies - moha.gov.vn
Mirum Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update - ADVFN
Mirum Pharmaceuticals Earnings Notes - Trefis
Mirum Pharmaceuticals (NASDAQ:MIRM) Downgraded by Wall Street Zen to "Buy" - MarketBeat
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update - ADVFN
Aug Reactions: Will Mirum Pharmaceuticals Inc. stock pay special dividendsStop Loss & Reliable Volume Spike Alerts - moha.gov.vn
Price-Driven Insight from (MIRM) for Rule-Based Strategy - Stock Traders Daily
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup - Chartmill
Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now - Finviz
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line - Yahoo Finance
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line - The Motley Fool
Rice Hall James & Associates LLC Sells 67,247 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals price target raised to $88 from $80 at Baird - MSN
What Analysts Think Is Changing the Story for Mirum Pharmaceuticals Now - Yahoo Finance
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Mirum pharmaceuticals director Saira Ramasastry sells $400k in shares By Investing.com - Investing.com Nigeria
Mirum Pharma director Grey sells $3.9 million in stock By Investing.com - Investing.com Nigeria
Mirum pharmaceuticals director Saira Ramasastry sells $400k in shares - Investing.com
Mirum Pharmaceuticals Executives Sell Shares - TradingView — Track All Markets
Mirum Pharma director Grey sells $3.9 million in stock - Investing.com
This Biotech Name Outperforms 93% Of Stocks, And It's In A Buy Zone - Investor's Business Daily
Mirum Pharmaceuticals joins elite list of stocks with 95-plus composite rating - MSN
Guidance Update: Will Mirum Pharmaceuticals Inc 08D stock sustain uptrend momentumPortfolio Return Summary & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
Mirum Pharmaceuticals: Rich In 2025, Richer (In Promise) In 2026? I Believe So (MIRM) - Seeking Alpha
Mirum: Maintaining Buy Rating On VOLIXIBAT PSC Treatment Data Q2 2026 (NASDAQ:MIRM) - Seeking Alpha
Squarepoint Ops LLC Decreases Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
How (MIRM) Movements Inform Risk Allocation Models - Stock Traders Daily
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):